TOP TEN perturbations for 1552674_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552674_at
Selected probe(set): 1552674_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552674_at (1552674_at) across 6672 perturbations tested by GENEVESTIGATOR:

rheumatoid arthritis study 69 (TNF; 20h; 1ng/ml; IL-17A; 20h; 1ng/ml) / rheumatoid arthritis study 69 (untreated)

Relative Expression (log2-ratio):0.72718
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 69 (TNF; 20h; 1ng/ml; IL-17A; 20h; 1ng/ml)
Joint synovial fibroblast samples from patients with rheumatoid arthritis after treatment with 1ng/ml TNF and 1ng/ml IL-17 for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and isolated from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.
Control rheumatoid arthritis study 69 (untreated)
Joint synovial fibroblast samples from patients with rheumatoid arthritis. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and prepared from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.

systemic lupus erythematosus study 13 (untreated) / normal PBMC sample

Relative Expression (log2-ratio):-0.7145734
Number of Samples:4 / 5
Experimental systemic lupus erythematosus study 13 (untreated)
Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists.
Control normal PBMC sample
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours.

osteoarthritis study 46 (TNF; 20h; 1ng/ml; IL-17A; 20h; 1ng/ml) / osteoarthritis study 46 (TNF; IL-17; baseline)

Relative Expression (log2-ratio):0.694952
Number of Samples:6 / 6
Experimental osteoarthritis study 46 (TNF; 20h; 1ng/ml; IL-17A; 20h; 1ng/ml)
Joint synovial fibroblast samples from patients with osteoarthritis after treatment with 1ng/ml TNF and 1ng/ml IL-17 for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and isolated from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.
Control osteoarthritis study 46 (TNF; IL-17; baseline)
Joint synovial fibroblast samples at baseline from patients with osteoarthritis before treatment with 1ng/ml TNF and/or IL-17 for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and prepared from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.

rheumatoid arthritis study 69 (TNF; 20h; 1ng/ml; IL-17A; 20h; 1ng/ml) / rheumatoid arthritis study 69 (TNF; IL-17A; baseline)

Relative Expression (log2-ratio):0.68627214
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 69 (TNF; 20h; 1ng/ml; IL-17A; 20h; 1ng/ml)
Joint synovial fibroblast samples from patients with rheumatoid arthritis after treatment with 1ng/ml TNF and 1ng/ml IL-17 for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and isolated from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.
Control rheumatoid arthritis study 69 (TNF; IL-17A; baseline)
Joint synovial fibroblast samples at baseline from patients with rheumatoid arthritis before treatment with 1ng/ml TNF and/or IL-17 for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and prepared from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.

osteoarthritis study 46 (TNF; 20h; 1ng/ml; IL-17A; 20h; 1ng/ml) / osteoarthritis study 46 (untreated)

Relative Expression (log2-ratio):0.67347956
Number of Samples:6 / 6
Experimental osteoarthritis study 46 (TNF; 20h; 1ng/ml; IL-17A; 20h; 1ng/ml)
Joint synovial fibroblast samples from patients with osteoarthritis after treatment with 1ng/ml TNF and 1ng/ml IL-17 for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and isolated from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.
Control osteoarthritis study 46 (untreated)
Joint synovial fibroblast samples from patients with osteoarthritis. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and prepared from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.

rheumatoid arthritis study 69 (TNF; 20h; 1ng/ml) / rheumatoid arthritis study 69 (untreated)

Relative Expression (log2-ratio):0.64982796
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 69 (TNF; 20h; 1ng/ml)
Joint synovial fibroblast samples from patients with rheumatoid arthritis after treatment with 1ng/ml TNF for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and isolated from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.
Control rheumatoid arthritis study 69 (untreated)
Joint synovial fibroblast samples from patients with rheumatoid arthritis. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and prepared from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.

dupilumab study 1 (300mg; lesional) / dupilumab study 1 (300mg; non-lesional)

Relative Expression (log2-ratio):0.64357996
Number of Samples:4 / 3
Experimental dupilumab study 1 (300mg; lesional)
Lesional skin tissue biopsies from patients with moderate-severe chronic atopic dermatitis obtained after therapy with dupilumab (300mg / wk / 4wks). 300mg of dupilumab was given once a week as subcutaneous injection, 4 injections in total. The samples were obtained 1 week after the last dupilumab injection. Dupilumab is an anti IL-4R mAb. ATC code:---
Control dupilumab study 1 (300mg; non-lesional)
Non-lesional skin tissue biopsies from patients with moderate-severe chronic atopic dermatitis obtained after therapy with dupilumab (300mg / wk / 4wks). 150mg of dupilumab was given once a week as subcutaneous injection, 4 injections in total. The samples were obtained 1 week after the last dupilumab injection. Dupilumab is an anti IL-4R mAb. ATC code:---

LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):0.61733913
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

rheumatoid arthritis study 69 (TNF; 20h; 1ng/ml) / rheumatoid arthritis study 69 (TNF; IL-17A; baseline)

Relative Expression (log2-ratio):0.6089201
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 69 (TNF; 20h; 1ng/ml)
Joint synovial fibroblast samples from patients with rheumatoid arthritis after treatment with 1ng/ml TNF for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and isolated from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.
Control rheumatoid arthritis study 69 (TNF; IL-17A; baseline)
Joint synovial fibroblast samples at baseline from patients with rheumatoid arthritis before treatment with 1ng/ml TNF and/or IL-17 for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and prepared from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.

osteoarthritis study 46 (TNF; 20h; 1ng/ml) / osteoarthritis study 46 (TNF; IL-17; baseline)

Relative Expression (log2-ratio):0.5460849
Number of Samples:6 / 6
Experimental osteoarthritis study 46 (TNF; 20h; 1ng/ml)
Joint synovial fibroblast samples from patients with osteoarthritis after treatment with 1ng/ml TNF for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and isolated from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.
Control osteoarthritis study 46 (TNF; IL-17; baseline)
Joint synovial fibroblast samples at baseline from patients with osteoarthritis before treatment with 1ng/ml TNF and/or IL-17 for 20 hours. Synovial fibroblasts were isolated from tissues discarded after synovectomy or joint replacement and prepared from digested synovial tissue and sorted for enriched CD45−, CD31−, CD235a−, Pdpn+ surface proteins. Cells were maintained in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 50 uM 2-mercaptoethanol, antibiotics (penicillin and streptomycin), and essential and nonessential amino acids and used between passages 5 and 8 for treatment.